Results 1 to 10 of about 1,201,120 (220)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer, 2018
Background There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown.
Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang, Zhen-ning Wang   +7 more
doaj   +2 more sources

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial

BMC Cancer, 2018
Background Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic ...
Seiji Ito, Yasuo Ohashi, Mitsuru Sasako
doaj   +2 more sources

Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer? [PDF]

Medicina
Background and Objectives: Colorectal cancer (CRC) poses a major global health challenge, with high incidence rates and ongoing treatment debates. Adjuvant chemotherapy benefits for high-risk subgroups, particularly stage II disease, remain controversial.
Goncagul Akdag, Deniz Isik, Akif Dogan, Sedat Yildirim, Oguzcan Kinikoglu, Alper Topal, Sila Oksuz, Ezgi Turkoglu, Heves Surmeli, Tugba Basoglu, Ozlem Nuray Sever, Hatice Odabas, Mahmut Emre Yildirim, Nedim Turan   +13 more
doaj   +2 more sources

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Nature Network Boston, 2023
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making ...
D. Kotani, E. Oki, Y. Nakamura, H. Yukami, S. Mishima, H. Bando, H. Shirasu, K. Yamazaki, J. Watanabe, M. Kotaka, K. Hirata, N. Akazawa, K. Kataoka, Shruti Sharma, Vasily N Aushev, A. Aleshin, T. Misumi, H. Taniguchi, I. Takemasa, T. Kato, Masaki Mori, T. Yoshino   +21 more
semanticscholar   +1 more source

Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims Adjuvant chemotherapy is the standard of care for resected stage II–IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial.
Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee   +12 more
doaj   +1 more source

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Journal of Clinical Oncology, 2022
PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
F. André, Nofisat Ismaila, K. Allison, W. Barlow, D. Collyar, S. Damodaran, N. L. Henry, K. Jhaveri, K. Kalinsky, N. Kuderer, A. Litvak, E. Mayer, L. Pusztai, R. Raab, A. Wolff, V. Stearns   +15 more
semanticscholar   +1 more source

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

JAMA Oncology, 2021
This randomized clinical trial evaluates the effect of postoperative radiotherapy on survival and safety in patients with pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy.
Z. Hui, Y. Men, Chen Hu, Jingjing Kang, Xin Sun, N. Bi, Zongmei Zhou, Jun Liang, J. Lv, Q. Feng, Z. Xiao, Dong-fu Chen, Yan Wang, Junling Li, Jie Wang, Shugeng Gao, Luhua Wang, Jie He   +17 more
semanticscholar   +1 more source

Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non‐elderly patients in stage III colorectal cancer

Annals of Gastroenterological Surgery, 2023
Aim We aimed to clarify the use of adjuvant chemotherapy and the prognosis of elderly colorectal cancer patients compared with non‐elderly patients, and the usefulness of sarcopenia as an indicator for the introduction and completion of adjuvant ...
Takuya Shiraishi, Hiroomi Ogawa, Ikuma Shioi, Naoya Ozawa, Katsuya Osone, Takuhisa Okada, Makoto Sohda, Ken Shirabe, Hiroshi Saeki   +8 more
doaj   +1 more source

Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. [PDF]

PLoS ONE, 2013
BACKGROUND: A phase III clinical trial has already shown the survival benefits of postoperative chemotherapy in gastric cancer. However, there are limited published data concerning the elderly.
Ying Jin, Miao-zhen Qiu, De-shen Wang, Dong-sheng Zhang, Chao Ren, Long Bai, Hui-yan Luo, Zhi-qiang Wang, Feng-hua Wang, Yu-hong Li, Rui-hua Xu   +10 more
doaj   +1 more source

Differences in the performance of adjuvant chemotherapy between hemodialysis and nonhemodialysis patients

Cancer Medicine, 2023
Background The survival of hemodialysis (HD) patients with cancer is poor, which may be caused by undertreatment due to renal dysfunction. Particularly, adjuvant chemotherapy after surgery may be considered optional because of its preventive nature. This
Taisuke Ishii, Tomone Watanabe, Takahiro Higashi   +2 more
doaj   +1 more source